Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Chartgod who wrote (622)	5/5/1998 5:04:00 PM
From: whitephosphorus	Respond to of 2135

Better bet for instant gratification.....IMHO Alfacel-ACEL This post is regarding Alfacel--ACEL Having been invested with this co. since 1986, and seeing what is happening with ENMD, I am more positive than ever that we are going to see our dreams come true soon. Dr. John Costanzi was interviewed on TV in Austin, TX yesterday and he urged caution on ENMD saying many drugs that worked on mice were shown not to be effective in humans. Dr. Costanzi is the same oncologist that was on CNN with his bikerider mesothelioma patient that was doing so well with Alfacell's drug onconase. The Austin American Stateman newspaper was full of articles quoting several oncologists who also caution on expections of efficacy and availability for human use. It appears that people who were uninformed of the FDA approval system badly misinterped the NY TIMES article thinking the first injection of humans in one year meant availability for treatment for all cancer patients when, in fact, they were referring to the beginning of Phase I human trials for toxicity. In reality, ENMD is where ACEL was is 1988. Granted it may not take them 10 years to get where we are today because of speeded up procedures, but I would think they are at least 6-7 years behind. With the recent addition of credible people on the board of directors (Don Conklin, former pres. of Schering-Plough, Martin Stadler, recently retired CFO of Hoffmann-LaRoche, and Dr.Stephen Carter, former head of worldwide drug development for Bristol-Myers Squibb, Alfacell is in an excellent position to move forward with their NDA in the 4th quarter. Surely we will have favorable PR and media attention at the time of filing, if not sooner. Maybe the long talked about marketing alliance will be announced soon! The time is right. The stockholders are ready. And Alfacell really does have something to tell the world about! I wish ENMD and their followers success. The world needs better cancer treatment in the worst way. But they are very premature with their enthusiasm.